3 Reasons BioMarin Pharmaceutical Stock Is a Buy Right Now
The rare-disease specialist BioMarin Pharmaceutical (NASDAQ: BMRN) posted an outstanding third-quarter earnings report yesterday after the closing bell. Specifically, the biotech crushed FactSet's consensus Q3 GAAP net income estimate by a whopping 75%, and beat the prevailing revenue forecast for the three-month period by a modest 1.16% as well. Investors, in turn, cheered this news by bidding up the company's stock by 3.83% in after-hours trading on moderate volume.
While better-than-expected earnings are always a plus from an investing standpoint, there's actually a lot more to like about this orphan drugmaker other than its encouraging Q3 results. Here are three additional reasons to consider buying this top biotech stock right now.
Image source: Getty Images.
Source Fool.com
